Technology Networks spoke with Peter Zipfell to learn more about the Innovation Summits and the key themes that will be explored at the events. In this interview, Peter also shares his thoughts on current trends in analytical technologies and software.

To learn more about the CMU Cloud Lab, the motivation behind the project and the benefits it will bring, Technology Networks spoke to Rebecca Doerge, PhD, dean, Mellon College of Science, Carnegie Mellon University, and Toby Blackburn, head of business development and research, Emerald Cloud Lab.

The ability to detect a tumor earlier, when it is smaller, reduces the impact of surgery and treatment, improving the prognosis for many patients. Dxcover has developed a new spectroscopic liquid biopsy approach that is able to identify brain tumors as small as 0.2 cm³ from a blood sample in as little as fifteen minutes.

This article explores how the expanded use of systematic, collaborative registries should allow the medical device, pharmaceutical and oncology communities to gain additional momentum on the road toward personalized cancer care.

Technology Networks recently spoke with Richard Hague, PolarityTE’s chief executive officer and president, to learn more about the science behind SkinTE and how it could overcome some of the limitations associated with other chronic wound treatments.

In recent years, a number of new cell and gene therapies have been developed to treat a variety of indications, including cancer and inherited retinal dystrophies. While these therapies have proven to be beneficial to patients, their scalability and manufacturability are two enduring challenges. Technology Networks spoke to Tara St.Amand, PhD, MBA, director of business technology, bioprocess at Corning to learn more about the key challenges faced when scaling up the manufacturing of cell products.

Technology Networks spoke to Linda De Jesus, senior vice president and chief commercial officer at Azenta Life Sciences to find out more about the announcement and how this will help drive innovation with greater speed and accuracy.

To find out more about HPIMS, Technology Networks spoke with Dr. Ching Wu, founder and chief executive officer at Excellims and a pioneer of HPIMS. In this interview, Dr. Wu talks about the advantages that the technique can offer in applications ranging from pharma PAT to clinical diagnostics, and discusses how Excellims is increasing accessibility to the technology.

Dimitris Argyropoulos explores the history of CASE and some of the ways it can be used to help scientists.

The service will enable oncologists, hematologists and other healthcare professionals to undertake rapid and extensive genomic analysis of cancer samples on an unprecedented scale in the UK.